Notizie AIOM – anno XVI n. 685

24 Luglio 2018

US Versus European Opinions on Upfront Therapy in Hodgkin Lymphoma

July 20, 2018 - United States’ versus European perspectives on the inclusion or exclusion of bleomycin in chemotherapy combinations for advanced Hodgkin lymphoma (HL), along with the value of interim positron emission tomography (PET), were discussed in a dual presentation ...
Leggi tutto

24 Luglio 2018

20 luglio 2018 – Divieto di inserimento nella stessa dispensazione di confezioni acquistate da strutture di diversa natura (pubblica/privata)

24 Luglio 2018

FDA approves first targeted treatment for patients with relapsed or refractory acute myeloid leukemia who have a certain genetic mutation

July 20, 2018 - The U.S. Food and Drug Administration today approved ivosidenib tablets for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) who have a specific genetic mutation. This is the first drug in its class (IDH1 inhibitors) ...
Leggi tutto

20 Luglio 2018

Scheda informativa condivisa da ISS, PMA, AIMAC e AIOM

Suggerimenti semplici su come preservare la fertilità prima dei trattamenti antitumorali, cofirmati da Istituto Superiore di Sanità (ISS), Registro Nazionale di Procreazione Medicalmente Assistita (PMA), Associazione Italiana Malati di Cancro, parenti e amici ...
Leggi tutto

20 Luglio 2018

FDA Grants Sacituzumab Govitecan Priority Review for Triple-Negative Breast Cancer

July 18, 2018 - The FDA has granted a priority review designation to a biologics license application (BLA) for sacituzumab govitecan for the treatment of patients with metastatic triple-negative breast cancer (mTNBC) following at least 2 prior therapies for metastatic disease, ...
Leggi tutto

20 Luglio 2018

FDA approves first cancer drug through new oncology review pilot that enables greater development efficiency

July 18, 2018 - The U.S. Food and Drug Administration today approved ribociclib in combination with an aromatase inhibitor for the treatment of pre/perimenopausal or postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative ...
Leggi tutto

20 Luglio 2018

Selinexor FDA Submission Started for Multiple Myeloma

July 18, 2018 - A rolling submission of an FDA new drug application (NDA) has been submitted for selinexor for the treatment of patients with penta-refractory multiple myeloma, according to Karyopharm Therapeutics, the manufacturer of the XPO1 inhibitor. The NDA is based ...
Leggi tutto

20 Luglio 2018

FDA Grants Atezolizumab Combo Breakthrough Designation for Frontline HCC

July 18, 2018 - The FDA has granted atezolizumab a breakthrough therapy designation for use in combination with bevacizumab as a first-line treatment for patients with advanced or metastatic hepatocellular carcinoma (HCC). The designation, which will expedite the development ...
Leggi tutto

20 Luglio 2018

EU and Japan reinforce their collaboration on inspections of medicine manufacturers

July 18, 2018 - The European Union (EU) and Japan have agreed to broaden the range of medicines for which they will recognise each other’s inspections of manufacturing sites. The current mutual recognition agreement (MRA) between the EU and Japan has been operational ...
Leggi tutto

20 Luglio 2018

Face-to-Face and Internet-Based Mindfulness-Based Cognitive Therapy Compared With Treatment as Usual in Reducing Psychological Distress in Patients With Cancer: A Multicenter Randomized Controlled Trial

Mindfulness-based cognitive therapy (MBCT) has been shown to alleviate psychological distress in patients with cancer. However, patients experience barriers to participating in face-to-face MBCT. Individual Internet-based MBCT (eMBCT) could be an alternative. The study aim ...
Leggi tutto

LAVORIAMO CON

News

TUMORE DEL SENO: 7 DONNE SU 10 COLPITE ANCHE DA VAMPATE DI CALORE. ‘NUOVA TERAPIA ORALE PUO’ CONTRASTARLE E FAVORIRE ADERENZA ALLE CURE’

FENILCHETONURIA: ITALIA RILEVANTE IN EUROPA PER INCIDENZA. “SCREENING NEONATALE PREVIENE DANNI NEUROLOGICI, MA NECESSARIA CONTINUITÀ DI CURA”

BRISTOL MYERS SQUIBB: “DA 80 ANNI IN ITALIA PORTIAMO INNOVAZIONE AI PAZIENTI”. IL LIVE PAINTING A PALAZZO MERULANA DISEGNA IL PONTE FRA ARTE E SCIENZA

LEUCEMIA LINFATICA CRONICA: L’ARTE DÀ VOCE ALL’ESPERIENZA DEI PAZIENTI. BEONE MEDICINES SOSTIENE IL PROGETTO DI PREGONI ALLA 61° BIENNALE D’ARTE DI VENEZIA

TUMORI PROSTATA: IN ITALIA 485MILA UOMINI VIVONO CON LA MALATTIA. SIUrO ED EUROPA UOMO ITALIA PRESENTANO LA “CARTA DELLE DOMANDE”

FOSSC: “BENE FINALMENTE L’ARRIVO DEI NUOVI LIVELLI ESSENZIALI D’ASSISTENZA DOPO BEN 9 ANNI DI ATTESA MA ORA SERVE CON RAPIDITA’ UN ULTERIORE AGGIORNAMENTO PER COPRIRE GLI ULTIMI 3 ANNI DI ACQUISIZIONE DI TRATTAMENTI INNOVATIVI”

MIASTENIA GRAVIS: IN ITALIA COLPITI PIU’ DI 15MILA UOMINI E DONNE. GLI ESPERTI, “PRIORITA’ LA PERSONALIZZAZIONE DELLE TERAPIE”

Notizie AIOM – anno XVI n. 685

US Versus European Opinions on Upfront Therapy in Hodgkin Lymphoma

20 luglio 2018 – Divieto di inserimento nella stessa dispensazione di confezioni acquistate da strutture di diversa natura (pubblica/privata)

FDA approves first targeted treatment for patients with relapsed or refractory acute myeloid leukemia who have a certain genetic mutation

Scheda informativa condivisa da ISS, PMA, AIMAC e AIOM

FDA Grants Sacituzumab Govitecan Priority Review for Triple-Negative Breast Cancer

FDA approves first cancer drug through new oncology review pilot that enables greater development efficiency

Selinexor FDA Submission Started for Multiple Myeloma

FDA Grants Atezolizumab Combo Breakthrough Designation for Frontline HCC

EU and Japan reinforce their collaboration on inspections of medicine manufacturers

Face-to-Face and Internet-Based Mindfulness-Based Cognitive Therapy Compared With Treatment as Usual in Reducing Psychological Distress in Patients With Cancer: A Multicenter Randomized Controlled Trial